{
    "question": "What do FDG-PET, amyloid PET, and tau PET scans each measure in the diagnosis of Alzheimer\u2019s disease?",
    "category": "Diagnosis",
    "essential_info": [
        "FDG-PET scans measure brain metabolism and show areas where nutrients are not properly used for energy.",
        "FDG-PET can help distinguish Alzheimer\u2019s disease from other dementias based on metabolic patterns.",
        "Amyloid PET scans detect amyloid plaques in the brain.",
        "Tau PET scans measure neurofibrillary tangles."
    ],
    "responses": [
        {
            "model": "gemma2-9b-it",
            "general_llm": "FDG-PET, amyloid PET, and tau PET scans are all valuable tools in the diagnosis of Alzheimer's disease, each offering a unique glimpse into the disease process.  \n\nHere's what each scan measures:\n\n* **FDG-PET (Fluorodeoxyglucose Positron Emission Tomography):** This scan measures glucose metabolism in the brain. It utilizes a radioactive tracer, FDG, which is taken up by active brain cells. In Alzheimer's disease, certain brain regions, particularly the hippocampus (important for memory) and cortex, show decreased glucose metabolism. FDG-PET can highlight these areas of reduced activity, suggesting brain damage characteristic of the disease.\n\n* **Amyloid PET:** This scan focuses on identifying amyloid plaques, a hallmark sign of Alzheimer's disease. Amyloid plaques are sticky protein deposits that build up between brain cells, disrupting communication and eventually leading to cell death. Amyloid PET scans use a tracer that binds specifically to amyloid plaques, allowing doctors to visualize their presence and distribution in the brain.\n\n* **Tau PET:** This scan targets tau tangles, another pathological feature of Alzheimer's disease. Tau tangles are twisted fibers of the tau protein that form inside brain cells. These tangles also interfere with cell function and contribute to nerve cell death. Tau PET scans utilize tracers that bind to tau tangles, enabling doctors to assess their accumulation in the brain.\n\n\n\nWhile each scan provides valuable information, they are often used in combination. The presence of both amyloid plaques and tau tangles, along with the FDG-PET findings of reduced glucose metabolism, strongly suggests Alzheimer's disease.  \n\n",
            "perfect_rag": "FDG-PET scans show areas of the brain where nutrients are not being used for energy. Amyloid PET imaging measures amyloid plaques in the brain. Tau PET imaging measures neurofibrillary tangles in the brain.  \n",
            "rag_pipeline": "The provided context describes FDG-PET and amyloid-PET scans but does not mention tau PET scans. \n\nFDG-PET scans visualize abnormalities in brain function, while amyloid-PET scans visualize abnormalities in brain histopathology, specifically amyloid-beta plaques.  \n"
        },
        {
            "model": "llama-3.1-8b-instant",
            "general_llm": "FDG-PET (Fluorodeoxyglucose Positron Emission Tomography), amyloid PET, and tau PET scans are advanced imaging techniques used in the diagnosis and evaluation of Alzheimer's disease. Each of these scans measures different aspects of brain pathology associated with the disease.\n\n1. **FDG-PET Scan:**\nFDG-PET scans measure glucose metabolism within the brain. In a healthy brain, areas with high activity and demand for energy require more glucose, which is then metabolized. In Alzheimer's disease, the metabolic activity in certain areas, particularly in the temporal and parietal lobes, is reduced. This decrease in glucose metabolism often correlates with cognitive decline and is thought to represent neuronal dysfunction and loss. The scan shows reduced tracer uptake in areas involved in Alzheimer's pathology, indicating decreased neuronal firing, which precedes significant neuronal loss. As such, FDG-PET can help identify areas of brain involvement but does not specifically identify or measure amyloid or tau proteins.\n\n2. **Amyloid PET Scan:**\nAmyloid PET scans, such as those using [18F]AV-1451, [18F]florbetapir, or [11C]Pittsburgh Compound B, detect the presence of beta-amyloid plaques in the brain. They measure the binding of amyloid tracers to amyloid beta peptides, which accumulate in the brains of individuals with Alzheimer's disease. Amyloid PET scans can detect the presence of amyloid plaques and assess their burden, which has been associated with Alzheimer's disease, although it is not exclusive to this condition. The presence of amyloid plaques is one hallmark of Alzheimer's disease. High amyloid burden in individuals without dementia may indicate an increased risk of developing it. However, it's essential to remember that an individual can have amyloid plaques without developing dementia and vice versa.\n\n3. **Tau PET Scan:**\nTau PET scans, such as those using [18F]MK-6240 or [18F]T807, detect the presence of tau protein aggregates in the brain. Tau is a critical component of neurofibrillary tangles, another hallmark of Alzheimer's disease pathology. These neurofibrillary tangles contain aggregated tau protein and are located within neurons. Studies have shown that tau accumulation is observed in individuals with Alzheimer's disease, and it is closely associated with cognitive decline. Tau PET scans can reveal the accumulation of aggregated tau in areas typically involved in Alzheimer's disease and are used for diagnostic purposes and for monitoring disease progression.\n\nThese imaging tools are increasingly being used as complementary diagnostic tools in Alzheimer's disease, particularly in the context of differential diagnosis and identifying patients suitable for potential therapeutic interventions.",
            "perfect_rag": "In the diagnosis of Alzheimer's disease, FDG-PET, amyloid PET, and tau PET scans each measure distinct aspects of the disease process. \n\nFDG-PET scans, also known as fluorodeoxyglucose PET imaging, measure areas of the brain where nutrients are not being properly used for energy, also known as metabolism. This helps distinguish between Alzheimer's disease and other types of dementia by identifying patterns in low metabolism areas.\n\nAmyloid PET imaging measures amyloid plaques in the brain, which are protein deposits linked to Alzheimer's disease. This test is primarily used in research but may be used to diagnose dementia in individuals with early or unusual symptoms.\n\nTau PET imaging measures neurofibrillary tangles in the brain, which are another characteristic of Alzheimer's disease. These tangles are abnormal structures formed by tau protein.",
            "rag_pipeline": "FDG-PET scans measure brain function, specifically glucose metabolism, which can indicate abnormalities in brain structure and function associated with Alzheimer's disease. \n\nAmyloid PET scans measure the presence of amyloid-beta (A\u03b2) plaques in the brain, a hallmark of Alzheimer's disease pathology. \n\nTau PET scans are not mentioned in the provided information, so we cannot determine what this scan measures in the diagnosis of Alzheimer's disease."
        },
        {
            "model": "llama-3.3-70b-versatile",
            "general_llm": "In the diagnosis of Alzheimer's disease, positron emission tomography (PET) scans play a crucial role in visualizing and measuring various aspects of brain function and pathology. Three types of PET scans commonly used in Alzheimer's diagnosis are FDG-PET, amyloid PET, and tau PET. Each of these scans measures different aspects of brain function and pathology, providing valuable insights into the diagnosis and progression of the disease.\n\n1. **FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) scans**: FDG-PET scans measure glucose metabolism in the brain. They work by injecting a small amount of a radioactive tracer, fluorodeoxyglucose (FDG), which is taken up by active brain cells. Areas of the brain with reduced glucose metabolism, indicative of impaired neural function, appear as areas of decreased uptake on the scan. In Alzheimer's disease, FDG-PET scans typically show reduced glucose metabolism in the temporal and parietal lobes, which are regions critical for memory and cognitive functions. This reduction in glucose metabolism is often seen in the early stages of the disease and can help differentiate Alzheimer's from other causes of dementia.\n\n2. **Amyloid PET scans**: Amyloid PET scans specifically measure the accumulation of amyloid-beta plaques in the brain, a hallmark of Alzheimer's disease pathology. These scans use radioactive tracers that bind to amyloid-beta deposits, allowing for the visualization of these plaques. The presence and extent of amyloid-beta deposition can be assessed, which helps in confirming the diagnosis of Alzheimer's disease. Amyloid PET scans are particularly useful in distinguishing Alzheimer's disease from other forms of dementia and in monitoring the progression of the disease over time. It's worth noting that while the presence of amyloid plaques is a characteristic feature of Alzheimer's, not all individuals with amyloid accumulation will develop the disease, and amyloid accumulation can also be found in cognitively normal elderly individuals.\n\n3. **Tau PET scans**: Tau PET scans are the latest addition to the diagnostic arsenal for Alzheimer's disease and measure the accumulation of tau protein tangles in the brain. Tau tangles, along with amyloid-beta plaques, are a key component of the neuropathological features of Alzheimer's disease. The tau protein is a microtubule-associated protein that, when hyperphosphorylated, can form neurofibrillary tangles that contribute to neuronal dysfunction and death. Tau PET scans use specific tracers that bind to tau protein, enabling the visualization of tau pathology in the brain. This can provide valuable information on the distribution and severity of tau pathology, which correlates with cognitive decline and disease progression. Tau PET scans hold promise for monitoring disease progression and the effects of potential therapeutic interventions targeting tau pathology.\n\nEach of these PET scans offers unique insights into the pathology and progression of Alzheimer's disease. By combining the information from FDG-PET, amyloid PET, and tau PET scans, clinicians can gain a more comprehensive understanding of an individual's disease state, which can inform diagnosis, prognosis, and treatment decisions. However, it's important to note that these scans are typically used in specific clinical contexts and in conjunction with other diagnostic tools, as part of a thorough diagnostic workup for Alzheimer's disease.",
            "perfect_rag": "In the diagnosis of Alzheimer's disease, three types of PET scans are utilized to measure distinct aspects of brain function and structure. \n\nFDG-PET scans measure areas of the brain where nutrients are not being properly used for energy, also known as metabolism. These scans can help identify patterns of low metabolism, which can distinguish Alzheimer's disease from other types of dementia.\n\nAmyloid PET scans measure the presence of amyloid plaques in the brain. This test is primarily used in research settings but may be employed in cases of unusual or very early onset dementia symptoms.\n\nTau PET scans measure the presence of neurofibrillary tangles in the brain. By detecting these tangles, tau PET scans can provide valuable information about the progression and extent of Alzheimer's disease.\n\nEach of these PET scans offers unique insights into the diagnosis and progression of Alzheimer's disease, allowing healthcare professionals to develop a more comprehensive understanding of the condition and its effects on the brain.",
            "rag_pipeline": "The answer is not available in the provided context for tau PET scans. However, FDG-PET measures brain function, specifically glucose metabolism, and amyloid-PET measures the presence of amyloid-beta (A\u03b2) tracers in the brain, which is an indicator of Alzheimer's disease pathology."
        },
        {
            "model": "meta-llama/llama-4-maverick-17b-128e-instruct",
            "general_llm": "In the diagnosis of Alzheimer's disease, three types of Positron Emission Tomography (PET) scans are used: FDG-PET, amyloid PET, and tau PET. Each scan measures different aspects of brain activity or pathology.\n\n1. **FDG-PET (Fluorodeoxyglucose-PET) Scans**: \n   - **Measure**: Glucose metabolism in the brain.\n   - **Significance**: Alzheimer's disease is associated with reduced glucose metabolism in certain areas of the brain. FDG-PET scans can detect these changes, which often correlate with cognitive decline. Reduced glucose uptake is typically seen in the temporal and parietal regions of the brain in patients with Alzheimer's disease.\n   - **Use in Diagnosis**: Helps in assessing the neurodegenerative aspect of Alzheimer's, supporting the diagnosis when used alongside clinical evaluation.\n\n2. **Amyloid PET Scans**:\n   - **Measure**: Amyloid plaques in the brain, a hallmark pathology of Alzheimer's disease.\n   - **Significance**: Amyloid plaques are deposits of amyloid-beta peptides that accumulate outside neurons. High levels of amyloid plaques are characteristic of Alzheimer's disease, although their presence alone is not definitive for the disease as they can also be found in cognitively normal individuals.\n   - **Use in Diagnosis**: Helps to determine if amyloid pathology, a key feature of Alzheimer's, is present. It's particularly useful in cases where the diagnosis is uncertain or to support a diagnosis of Alzheimer's disease.\n\n3. **Tau PET Scans**:\n   - **Measure**: Tau protein tangles in the brain, another hallmark pathology of Alzheimer's disease.\n   - **Significance**: Tau tangles are abnormal accumulations of tau protein inside neurons. The distribution and density of tau tangles correlate more closely with cognitive decline and neurodegeneration than amyloid plaques. \n   - **Use in Diagnosis**: Assesses the extent of tau pathology, which is closely linked to the severity of Alzheimer's disease symptoms. Tau PET can help in understanding the progression of the disease.\n\nIn summary, these PET scans provide complementary information:\n- **FDG-PET** assesses the functional impact of the disease on brain metabolism.\n- **Amyloid PET** detects the presence of amyloid pathology.\n- **Tau PET** measures the extent of tau pathology, closely related to cognitive symptoms.\n\nTogether, they contribute to a more comprehensive understanding and diagnosis of Alzheimer's disease, helping clinicians assess disease pathology and progression.",
            "perfect_rag": "FDG-PET, amyloid PET, and tau PET scans are used in the diagnosis of Alzheimer's disease to measure different aspects of the disease. \n\n1. FDG-PET scans measure areas of the brain where nutrients are not being properly used for energy, known as metabolism. Patterns in areas of low metabolism can help distinguish between Alzheimer's disease and other types of dementia.\n\n2. Amyloid PET scans measure amyloid plaques in the brain. This test is mainly used in research but may be used if a person has unusual or very early onset of dementia symptoms.\n\n3. Tau PET scans measure neurofibrillary tangles in the brain.\n\nThese PET scans help diagnose Alzheimer's disease by capturing images of the disease process and detecting specific brain changes associated with the disease.",
            "rag_pipeline": "FDG-PET measures brain function, specifically glucose metabolism, while amyloid-PET measures amyloid-beta (A\u03b2) histopathology. The context does not mention tau PET scans. Therefore, information about tau PET scans is not available. \n\nTo provide a complete answer to the question: FDG-PET measures glucose metabolism in the brain, and amyloid-PET measures amyloid-beta (A\u03b2) histopathology. The measurement of tau PET scans is not available in the provided context."
        },
        {
            "model": "qwen/qwen3-32b",
            "general_llm": "<think>\nOkay, let's see. The user is asking about FDG-PET, amyloid PET, and tau PET scans in the context of Alzheimer's diagnosis. I need to explain what each of these scans measures.\n\nFirst, FDG-PET. I remember FDG is fluorodeoxyglucose, a glucose analog. PET scans with FDG look at metabolic activity in the brain. Since Alzheimer's causes decreased glucose metabolism in certain areas like the temporal and parietal lobes, this scan helps identify those regions. But it's not specific to Alzheimer's; other conditions can cause similar metabolic changes.\n\nNext, amyloid PET. This detects beta-amyloid plaques. Amyloid plaques are a hallmark of Alzheimer's. Scans use tracers that bind to these plaques, visible on the images. Positive amyloid PET indicates amyloid buildup. However, some people with amyloid can have normal cognition, so it's not enough on its own.\n\nThen tau PET. It detects tau tangles. Tau tangles are another key feature, forming in different brain regions as the disease progresses. Tau PET helps show the distribution and density of these tangles. This can determine the disease's stage and correlate with cognitive decline.\n\nPutting it together: FDG-PET shows metabolic patterns, amyloid PET checks for plaques, and tau PET for tangles. Clinically, they're used alongside other tests. For example, amyloid scans confirm pathology, FDG shows atrophy patterns, and tau might help track progression. Need to mention that none are standalone but part of a diagnostic workup. Also note that FDG can be used for monitoring, while amyloid and tau are more about pathology confirmation. Make sure to clarify limitations, like amyloid presence not guaranteeing Alzheimer's. Avoid jargon where possible, explain the tracers, and how they aid in distinguishing Alzheimer's from other dementias. Check if any newer tracers or updated guidelines. Ensure clarity on each scan's role and their complementary use.\n</think>\n\nFDG-PET, amyloid PET, and tau PET are specialized imaging techniques used in the evaluation of Alzheimer\u2019s disease (AD), each providing distinct insights into the brain\u2019s structure, metabolism, and pathology. Here\u2019s how each scan contributes to diagnosis:\n\n---\n\n### **1. FDG-PET (Fluorodeoxyglucose Positron Emission Tomography)**\n- **What it measures**: Brain metabolic activity, specifically glucose uptake.  \n- **Clinical relevance**:  \n  - In Alzheimer\u2019s, certain brain regions (e.g., **posterior cingulate, temporoparietal cortex**) show **reduced glucose metabolism** due to neurodegeneration.  \n  - Helps identify **metabolic patterns** associated with AD, which differ from other neurodegenerative conditions (e.g., frontotemporal dementia).  \n  - Can monitor disease progression or treatment response by tracking metabolic changes over time.  \n- **Limitations**: Not specific to Alzheimer\u2019s\u2014reduced metabolism can occur in other conditions (e.g., vascular dementia, depression).  \n\n---\n\n### **2. Amyloid PET Scans**\n- **What it measures**: **Amyloid-beta (A\u03b2) plaques**, one of the two hallmark pathological features of Alzheimer\u2019s (alongside tau tangles).  \n- **Clinical relevance**:  \n  - Detects the **presence of amyloid plaques** in the brain, even in cognitively normal individuals, indicating preclinical AD.  \n  - Distinguishes Alzheimer\u2019s from **vascular dementia** or **Lewy body dementia**, which lack amyloid pathology.  \n  - Used cautiously in research and clinical settings to confirm amyloid pathology in individuals with mild cognitive impairment (MCI) or early symptoms.  \n- **Limitations**:  \n  - Amyloid accumulation does not always equate to AD (e.g., some older adults have amyloid without cognitive decline).  \n  - High cost and limited availability restrict routine clinical use.  \n\n---\n\n### **3. Tau PET Scans**\n- **What it measures**: **Neurofibrillary tangles** composed of hyperphosphorylated **TAU protein**, another key AD pathology.  \n- **Clinical relevance**:  \n  - Maps the **distribution, severity, and progression** of tau tangles. Unlike amyloid plaques, tau tangles correlate closely with cognitive decline and neuronal loss.  \n  - Helps stage AD (e.g., early tangles in the entorhinal cortex vs. later involvement of the neocortex).  \n  - Differentiates AD from **non-AD tauopathies** (e.g., frontotemporal dementia, progressive supranuclear palsy) by unique tangle patterns.  \n- **Limitations**:  \n  - Still investigational in many regions due to challenges in tracer development and validation.  \n  - Not yet widely adopted in standard clinical practice.  \n\n---\n\n### **Synergy in Alzheimer\u2019s Diagnosis**\n- These scans are **complementary**:  \n  - **Amyloid PET** confirms AD pathology, while **tau PET** tracks its progression.  \n  - **FDG-PET** provides functional insights into brain activity, aiding differential diagnosis and assessing disease severity.  \n- Together, they help clinicians and researchers:  \n  - Confirm or exclude AD in atypical cases.  \n  - Monitor disease progression in clinical trials.  \n  - Tailor interventions (e.g., amyloid-targeting therapies) to amyloid-positive patients.  \n\n---\n\n### **Key Takeaway**\nWhile no single imaging modality is diagnostic on its own, the combination of FDG-PET, amyloid PET, and tau PET provides a comprehensive view of Alzheimer\u2019s pathology, metabolism, and progression. Their use is most valuable in research, early detection, and differential diagnosis in complex cases. Always interpreted alongside clinical history, cognitive tests, and other biomarkers (e.g., cerebrospinal fluid analysis).",
            "perfect_rag": "<think>\nOkay, so the user is asking about FDG-PET, amyloid PET, and tau PET scans and what each of them measures in the context of Alzheimer's diagnosis. Let me start by looking through the provided context.\n\nFirst, there's a section on brain scan images for Alzheimer's diagnosis. The context mentions FDG-PET scans showing areas where the brain isn't using nutrients for energy properly, which is metabolism. It differentiates between healthy areas (black and blue) and those with issues (green, yellow, red) indicating worsening metabolism. So FDG-PET is about metabolism.\n\nThen, for amyloid PET imaging, it says these measure amyloid plaques in the brain. The context notes they're mainly used in research but can be used for unusual or very early onset cases. So this scan checks for accumulation of amyloid plaques, a hallmark of Alzheimer's.\n\nTau PET imaging is mentioned next. It measures neurofibrillary tangles in the brain. These tangles are another key biomarker for Alzheimer's. The context also mentions that tau PET is part of PET imaging that captures disease processes through tracers.\n\nI should make sure to clarify each scan's purpose. FDG-PET looks at metabolism, amyloid-PET at amyloid plaques, and tau-PET at tau tangles. The user might be a patient or caregiver looking to understand different diagnostic methods. They might need this info to decide on testing options or understand a diagnosis. They might also be interested in how these scans differ from each other and their roles in diagnosis. The answer should clearly differentiate each scan's function based on the context provided. Also, note that FDG-PET helps distinguish Alzheimer's from other dementias by metabolism patterns, amyloid-PET checks for plaques, and tau-PET looks at tangles. The context doesn't mention other uses beyond what's given, so I shouldn't add anything from external knowledge. Need to keep it concise, accurate, and using the terms from the source material.\n</think>\n\nFDG-PET, amyloid PET, and tau PET scans each measure distinct biological aspects of the brain in the diagnosis of Alzheimer\u2019s disease:\n\n1. **FDG-PET (Fluorodeoxyglucose PET) Scans**:  \n   These scans assess areas of the brain where energy metabolism is impaired. Specifically, they identify regions with reduced nutrient utilization for energy, which is often characteristic of Alzheimer\u2019s. Healthy metabolism appears as darker hues (black/blue), while diminished activity\u2014linked to Alzheimer\u2019s progression\u2014appears as brighter colors (green, yellow, red). FDG-PET helps differentiate Alzheimer\u2019s from other forms of dementia by visualizing patterns of metabolic decline.\n\n2. **Amyloid PET Scans**:  \n   These scans detect the presence of amyloid plaques in the brain, a hallmark pathology of Alzheimer\u2019s disease. Amyloid plaques are abnormal clusters of beta-amyloid protein that accumulate in the brain as the disease progresses. Amyloid PET is particularly valuable in cases of early-onset dementia or atypical symptoms to confirm or rule out Alzheimer\u2019s.\n\n3. **Tau PET Scans**:  \n   Tau PET imaging measures neurofibrillary tangles composed of tau protein, another key feature of Alzheimer\u2019s. These tangles disrupt communication in brain cells and worsen as the disease advances. Tau PET helps track the distribution and severity of tangles, providing insights into disease stages and progression.\n\nEach test provides unique information: FDG-PET highlights functional metabolic changes, amyloid PET identifies plaques, and tau PET reveals tangle formation. Together, these scans support a comprehensive diagnosis of Alzheimer\u2019s during life, alongside clinical evaluations and other biomarker assessments.",
            "rag_pipeline": "<think>\nOkay, let me try to figure out the answer here. The user is asking what FDG-PET, amyloid PET, and tau PET scans each measure in the diagnosis of Alzheimer's disease.\n\nFirst, I'll look at the context provided. The title mentions FDG and amyloid-PET, so they're probably going to talk about those. The section starts by saying that biomarkers for early detection are important because they can pick up changes before symptoms show. They mention that PET imaging with amyloid-beta tracers and FDG is used for diagnosis.\n\nIn the context, FDG-PET is mentioned as using 2-[(18)F]fluoro-2-Deoxy-D-glucose. FDG is a glucose analog, so I remember that FDG-PET measures metabolic activity. Brain regions with lower glucose metabolism would show up as reduced FDG uptake. In Alzheimer's, certain areas like the temporoparietal and cingulate regions have decreased metabolism, which FDG-PET can detect. That's probably the main function of FDG-PET here.\n\nThen there's amyloid-PET, which uses amyloid-beta tracers. Amyloid-beta is one of the pathological hallmarks of Alzheimer's, forming plaques in the brain. So amyloid-PET would measure the presence and distribution of these A\u03b2 plaques. The context does mention that amyloid-PET is used to visualize histopathology, specifically A\u03b2 abnormalities.\n\nThe user also asked about tau PET scans. The context provided doesn't explicitly mention tau PET. The title and section talk about FDG and amyloid, but there's no direct information on tau. The paper being reviewing FDG and amyloid-PET in AD patients and non-demented at-risk individuals. Since tau is another protein involved in Alzheimer's (neurofibrillary tangles), but the context doesn't discuss tau PET. So even though the user mentioned it in their question, the context doesn't provide info on tau PET, so I shouldn't include it beyond what's there.\n\nThe discussion part mentions combining FDG-PET (symptoms-sensitive) with A\u03b2-PET (pathology-specific). This suggests FDG-PET relates more to functional aspects (like metabolism) and symptoms, while amyloid-PET is about pathology.\n\nSo putting it all together: FDG-PET measures metabolic activity (glucose metabolism), amyloid-PET measures A\u03b2 plaques. There's no information on tau PET in the context, so I can't answer that part. The user might be expecting tau to be covered, but based on the context provided, it's not there. Therefore, I need to answer only for FDG and amyloid, and state that tau isn't covered in the context.\n</think>\n\nThe context provided states that **FDG-PET** (using 2-[(18)F]fluoro-2-deoxy-D-glucose) measures metabolic activity in the brain through glucose uptake. It detects functional impairments, such as reduced metabolic activity in regions like the temporoparietal and cingulate cortices, which are characteristic of Alzheimer\u2019s disease (AD) and correlate with symptom severity. This makes FDG-PET sensitive to clinical symptoms but not directly to pathological changes.  \n\n**Amyloid-PET** measures the presence and distribution of amyloid-beta (A\u03b2) pathology in the living brain. It detects abnormal A\u03b2 plaques, a histopathological hallmark of AD, and is considered a specific marker for the underlying disease process, even in asymptomatic or preclinical stages.  \n\nThe role of **tau PET** is not explicitly discussed in the provided context. The text does not mention tau pathology (e.g., neurofibrillary tangles) or tau-specific imaging tracers.  \n\nIn summary, FDG-PET reflects metabolic dysfunction linked to symptoms, while amyloid-PET tracks A\u03b2 plaques related to histopathology. Tau PET is not described in the context."
        }
    ]
}